



# OHIO VALLEY MEDICAL CENTER

2000 Eoff Street  
Wheeling, WV 26003

December 1, 2010

Division of Nuclear Materials Safety  
U.S. Nuclear Regulatory Commission  
Region 1  
475 Allendale Road  
King of Prussia, PA 19406-1415

Br. 1

2010 DEC 20 AM 11: 22

RECEIVED  
REGION 1

Re: Request to ammend NRC License Number 47-17282-01

03012498

Gentlemen:

We request to amend our license as follows:

1. Delete name of Kelby L. Frame, M.D., Authorized User, in Item 12.B of our license. He is no longer affiliated with our facility.
2. Delete name of Mark C. Kenamond, M.D., Authorized User, in Item 12.B of our license. He is no longer affiliated with our facility.
3. Add name of Dr. Dana G. Borgeson, D.O., Authorized User, in Item 12.B of our license. He will be listed as 35.100, 35.200, and 35.300 Authorized User. Enclosed you will find the previous Radioactive Materials License he was listed on for your edification.

Please do no hesitate to contact the undersigned for clarification.

Thank you for your assistance with this matter.

Sincerely,

Yong K. Park, Ph.D.  
Radiation Safety Officer

ENCLOSURE

574133  
NMSS/RGN1 MATERIALS-002



DEPARTMENT OF THE NAVY  
OFFICE OF THE CHIEF OF NAVAL OPERATIONS  
2000 NAVY PENTAGON  
WASHINGTON, DC 20350-2000

IN REPLY REFER TO

6470  
Ser N456S/9U158711  
5 February 2009

From: Chairman, Naval Radiation Safety Committee  
To: Commanding Officer, Naval Hospital, 100 Brewster Blvd.,  
Camp Lejeune, NC 28547-2538

Subj: NAVAL RADIOACTIVE MATERIALS PERMIT (NRMP) 32-68093-11NP,  
AMENDMENT NO. 19

Ref: (a) OPNAVINST 6470.3A  
(b) Title 10 Code of Federal Regulations Part 35  
(10 CFR 35)  
(c) Title 49 Code of Federal Regulations  
(d) NAVHOSP Camp Lejeune ltr 6470 Ser 05XR/2009-68 of  
15 Jan 08

Encl: (1) NRMP Number 32-68093-11NP, Amendment No. 19

1. Per references (a), (b) and (c), your request in reference (d), to amend the subject permit has been reviewed and approved by the Naval Radiation Safety Committee. Enclosure (1) is the record of approval.

2. The permit amendment has the following change:

Permit condition 12 is revised to add CDR Dana G. Borgeson, MC, USN as an authorized user (AU) for medical uses under Parts 35.100 and 35.200, and diagnostic studies and oral Iodine-131 therapy under Part 35.300 of reference (b). He is approved on the basis of training and experience as required by 35.190, 35.290, and the uses of I-131 under 35.392(c), as documented in reference (d). He meets the recentness of training and experience requirements in Part 35.59. He is licensed by the state of North Carolina.

3. Review enclosure (1) carefully to be sure that all conditions are understood. Changes as a result of this amendment are printed in bold typeface.

4. For additional information, please contact Ms. Karen O. Ely, Navy and Marine Corps Public Health Center, at DSN 377-0767 or

Subj: NAVAL RADIOACTIVE MATERIALS PERMIT (NRMP) 32-68093-11NP,  
AMENDMENT NO. 19

(757) 953-0767, facsimile (757) 953-0670 or E-mail at  
karen.ely@med.navy.mil.

  
L. L. FRAGOSO  
By direction

Copy to:  
BUMED (M3B42)  
NAVMED SUPPCMD  
NAVMED EAST  
NAVMCPUBHLTHCEN

**NAVAL RADIOACTIVE MATERIALS PERMIT**

*Pursuant to the authority stated in OPNAVINST 6470.3, Naval Radiation Safety Committee, and in reliance on statements made by the applicant, permission is hereby granted for the acquisition, receipt, possession, use, storage and disposal of radioactive materials listed below subject to the conditions listed in this permit.*

<p><b>1 - COMMAND</b></p> <p>Commanding Officer                  Naval Hospital                  100 Brewster Blvd                  Camp Lejeune, NC 28547-2538</p>	<p>In accordance with the letter dated 15 January 2009</p>
	<p><b>2 - PERMIT NO.</b> 32-68093-11NP</p> <p>Is amended in its entirety to read as follows:</p>
	<p><b>3 - AMENDMENT NO.</b> 19</p>
	<p><b>4 - DOCKET NO.</b></p>
	<p><b>5 - EXPIRATION DATE</b>                  31 March 2018</p>

<b>6 - RADIOACTIVE MATERIAL</b>	<b>7 - CHEMICAL/ PHYSICAL FORM</b>	<b>8 - MAXIMUM QUANTITY AUTHORIZED</b>
A. Any byproduct material permitted by 10 CFR 35.100.	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200.	B. Any	B. As needed
C. I-131 for diagnostic studies and outpatient hyperthyroid therapy permitted by 10 CFR 35.300.	C. Capsule	C. As needed, not to exceed 30 millicuries, (1,110 megabecquerels) of I- 131
D. Any byproduct material permitted in 10 CFR 35.65.	D. Any	D. No single source to exceed the maximum activity specified in 10 CFR 35.65

**UNITED STATES NAVAL RADIATION SAFETY COMMITTEE**

**SUPPLEMENTARY SHEET****United States Naval Radiation Safety Committee****Radioactive Materials Permit****PERMIT NO.**32-68093-11NP**AMENDMENT NO.**19

## 9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100 for which a written directive is not required.
- B. Any imaging and localization study permitted by 10 CFR 35.200 for which a written directive is not required.
- C. Iodine-131 in capsule form for use in any diagnostic study or outpatient hyperthyroid therapy as specified in 10 CFR 35.300 for which a written directive is required.
- D. Any sources of byproduct material used as calibration, transmission and reference sources as described in 10 CFR 35.65.

**PERMIT CONDITIONS**

- 10. Radioactive material authorized by this Permit shall be stored and used only at Naval Hospital/100 Brewster Blvd. (main hospital), Camp Lejeune, NC.
- 11. The Radiation Safety Officer for the use of radioactive material authorized by this Permit is Frank A. Aversa.
- 12. Radioactive material listed in Item 6 is also authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use:

**SUPPLEMENTARY SHEET****United States Naval Radiation Safety Committee****Radioactive Materials Permit****PERMIT NO.**32-68093-11NP**AMENDMENT NO.**19Authorized UsersMaterial and Use

Dana G. Borgeson, D.O.  
(CDR, MC, USN)

10 CFR 35.100, 35.200 and  
outpatient I-131 hyperthyroid  
therapy and diagnostic studies  
as specified in 10 CFR 35.300.

Brian A. Singleton, M.D.  
(LCDR, MC, USN)

10 CFR 35.100, 35.200 and  
outpatient I-131 hyperthyroid  
therapy and diagnostic studies  
as specified in 10 CFR 35.300.

Roger T. Tomihama, M.D.  
(LT, MC, USN)

10 CFR 35.100, 35.200 and  
outpatient I-131 hyperthyroid  
therapy and diagnostic studies  
as specified in 10 CFR 35.300.

C. Radioactive material shall be used by, or under the supervision of, individuals designated by the Command's Radiation Safety Committee.

13. The Command shall conduct a physical inventory of all sealed sources every six months to account for all sealed sources and devices, received and possessed under this permit per 10 CFR 35.67. In addition, waste shall be inventory every six months. Records of the inventory shall be maintained for five years from the date of the inventory. Records shall include the quantities and kinds of radioactive material, manufacturer's name and model/lot number, location of use or storage, and the date of the inventory and shall be signed by the Radiation Safety Officer.
14. Sealed sources or detector cells containing permitted material shall not be opened or sources removed from source holders by the permittee.
15. The permittee shall not acquire radioactive material in a sealed source or device unless the source or device has been registered with the Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an agreement State.

**SUPPLEMENTARY SHEET****United States Naval Radiation Safety Committee****Radioactive Materials Permit****PERMIT NO.**32-68093-11NP**AMENDMENT NO.**19

16. The permittee is authorized receipt and transfer of any permitted material in accordance with the provisions of 10 CFR Part 20, 10 CFR Part 71, and 49 CFR Parts 171-173.
17. The Radiation Safety Officer or a qualified designee will personally approve all transfers of radioactive material covered by this Permit. This includes a review of the packaging, labeling, and documentation of each outgoing shipment as well as the receipt process for each incoming shipment.
18. All personnel involved in the receipt, handling, preparation or transfer/shipment of radioactive material shall be trained in accordance with 49 CFR 172 Subpart H. Documentation of training and testing shall be maintained for three years.
19. The Command shall comply with and maintain current copies of the following:
  - A. Title 10, Code of Federal Regulations, Parts 19, 20, 21, 30, 35 and 71; and 49 CFR Parts 171-178.
  - B. BUMEDINST 6470.20.
  - C. OPNAVINST 6470.3A.
  - D. NAVMED P-5055.
  - E. NAVENVIRHLTHCEN/OPNAV Information Notices and Bulletins.
20. Except as specifically provided otherwise by this Permit, the Command shall possess and use radioactive material described in this Permit in accordance with statements, representations, and procedures contained in the following correspondence:
  - A. NAVHOSP Camp Lejeune ltr 6470 Ser 05XR-008 dated 15 Nov 07. (Am 16: Renewal application). Also removal of "accelerator produced" from permit conditions due to NARM rule, and change of name of NEHC to NMCPUBHLTHCEN.)
  - B. NAVHOSP Camp Lejeune ltr 6470 Ser 05XR dated 16 Jul 07. (Delete Dr. Joseph W. Fischer and LCDR Christopher Minette

**SUPPLEMENTARY SHEET****United States Naval Radiation Safety Committee****Radioactive Materials Permit****PERMIT NO.**32-68093-11NP**AMENDMENT NO.**19

as AU due to leaving the command).

- C. NAVHOSP Camp Lejeune ltr 6470 Ser 05XR/001 dated 29 Oct 07.  
(Modification of scope of AU duties to include hyperthyroid therapy and diagnostic studies permitted by 10 CFR 35.300).
- D. NAVHOSP Camp Lejeune ltr 6470 Ser 05XR/2008-162 dated 06 Mar 08.  
(Am 17: Change of RSO from Glenee Smith to Frank Aversa; addition of LT R. Tomihama, MC, USN as AU for 35.100, 35.200 uses and hyperthyroid therapy and diagnostic studies permitted by 10 CFR 35.300; addition of Room S156A as a RAM storage area).
- E. NAVHOSP Camp Lejeune ltr 6470 Ser 05XR/2008-642 dated 01 Apr 08.  
(Am 17: Expanded the dimensions of Nuclear Medicine imaging Room #S144 to accommodate a new gamma camera).
- F. NAVHOSP Camp Lejeune ltr 6460 Ser 05XR/2008-1373 dated 29 Apr 08.  
(Delete Dr. Edward J. Easton as Au due to leaving the command).
- G. NAVHOSP Camp Lejeune ltr 6460 Ser 05XR/2008-3443 dated 21 Jul 08.  
(Change the use of the Nuclear Medicine Hot Lab, Room #S155, to include location to administer radiopharmaceuticals).
- H. NAVHOSP Camp Lejeune ltr 6460 Ser 05XR/2008-3977 dated 13 Aug 08.  
(Am: 18: Add Electrocardiogram (EKG) Room #N-405 as an additional location to administer radiopharmaceuticals).
- I. NAVHOSP Camp Lejeune ltr 6460 Ser 05XR/2009-68 dated 15 Jan 09.  
(Am: 19: addition of CDR D. Borgeson, MC, USN as AU for 35.100, 35.200 uses and hyperthyroid therapy and diagnostic studies permitted by 10 CFR 35.300).

**SUPPLEMENTARY SHEET****United States Naval Radiation Safety Committee****Radioactive Materials Permit****PERMIT NO.**32-68093-11NP**AMENDMENT NO.**19

21. The Command shall maintain records for review by the Naval Radiation Safety Committee sufficient to document operational compliance with the above requirements and other conditions of this Permit.

DATE:

5 Feb 2009  
L. L. FRAGOSO

Captain, MSC, USN

Executive Secretary

Naval Radiation Safety Committee

This is to acknowledge the receipt of your letter application dated

12/1/2010, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment (47-17282-01) There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 574133.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.